Suppr超能文献

通过对一组病毒RNA结合分子进行表型分析鉴定出的新型冠状病毒2型抑制剂

SARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules.

作者信息

Simba-Lahuasi Alvaro, Cantero-Camacho Ángel, Rosales Romel, McGovern Briana Lynn, Rodríguez M Luis, Marchán Vicente, White Kris M, García-Sastre Adolfo, Gallego José

机构信息

Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia, 46001 Valencia, Spain.

Escuela de Doctorado, Universidad Católica de Valencia, 46001 Valencia, Spain.

出版信息

Pharmaceuticals (Basel). 2022 Nov 22;15(12):1448. doi: 10.3390/ph15121448.

Abstract

Antiviral agents are needed for the treatment of SARS-CoV-2 infections and to control other coronavirus outbreaks that may occur in the future. Here we report the identification and characterization of RNA-binding compounds that inhibit SARS-CoV-2 replication. The compounds were detected by screening a small library of antiviral compounds previously shown to bind HIV-1 or HCV RNA elements with a live-virus cellular assay detecting inhibition of SARS-CoV-2 replication. These experiments allowed detection of eight compounds with promising anti-SARS-CoV-2 activity in the sub-micromolar to micromolar range and wide selectivity indexes. Examination of the mechanism of action of three selected hit compounds excluded action on the entry or egress stages of the virus replication cycle and confirmed recognition by two of the molecules of conserved RNA elements of the SARS-CoV-2 genome, including the highly conserved S2m hairpin located in the 3'-untranslated region of the virus. While further studies are needed to clarify the mechanism of action responsible for antiviral activity, these results facilitate the discovery of RNA-targeted antivirals and provide new chemical scaffolds for developing therapeutic agents against coronaviruses.

摘要

治疗新型冠状病毒肺炎(SARS-CoV-2)感染以及控制未来可能出现的其他冠状病毒疫情都需要抗病毒药物。在此,我们报告了对抑制SARS-CoV-2复制的RNA结合化合物的鉴定和表征。通过筛选一个先前显示能与HIV-1或HCV RNA元件结合的抗病毒化合物小文库,并采用检测SARS-CoV-2复制抑制的活病毒细胞试验来检测这些化合物。这些实验检测到了8种具有良好抗SARS-CoV-2活性的化合物,其活性范围在亚微摩尔至微摩尔之间,且具有较宽的选择性指数。对三种选定的活性化合物的作用机制进行研究后发现,它们对病毒复制周期的进入或释放阶段没有作用,并证实其中两种分子能识别SARS-CoV-2基因组的保守RNA元件,包括位于病毒3'非翻译区的高度保守的S2m发夹结构。虽然还需要进一步研究来阐明负责抗病毒活性的作用机制,但这些结果有助于发现以RNA为靶点的抗病毒药物,并为开发抗冠状病毒治疗药物提供新的化学支架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c0a/9784969/42c3f50bec1b/pharmaceuticals-15-01448-g001.jpg

相似文献

1
SARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules.
Pharmaceuticals (Basel). 2022 Nov 22;15(12):1448. doi: 10.3390/ph15121448.
2
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
3
Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome.
J Virol. 2021 Jun 24;95(14):e0066321. doi: 10.1128/JVI.00663-21.
4
Current Strategies of Antiviral Drug Discovery for COVID-19.
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
5
The highly conserved stem-loop II motif is dispensable for SARS-CoV-2.
bioRxiv. 2023 Mar 16:2023.03.15.532878. doi: 10.1101/2023.03.15.532878.
7
The Highly Conserved Stem-Loop II Motif Is Dispensable for SARS-CoV-2.
J Virol. 2023 Jun 29;97(6):e0063523. doi: 10.1128/jvi.00635-23. Epub 2023 May 18.
8
Targeting a conserved structural element from the SARS-CoV-2 genome using l-DNA aptamers.
RSC Chem Biol. 2021 Oct 20;3(1):79-84. doi: 10.1039/d1cb00172h. eCollection 2022 Jan 5.
9
Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M by virtual screenings and hit optimization.
Antiviral Res. 2022 Aug;204:105350. doi: 10.1016/j.antiviral.2022.105350. Epub 2022 Jun 7.
10

引用本文的文献

本文引用的文献

1
Novel HIV-1 RNA biogenesis inhibitors identified by virtual pharmacophore-based screening.
Biochem Pharmacol. 2023 Sep;215:115734. doi: 10.1016/j.bcp.2023.115734. Epub 2023 Aug 6.
3
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.
J Biomed Sci. 2022 Sep 6;29(1):65. doi: 10.1186/s12929-022-00847-6.
4
Pharmacophore-Based Discovery of Viral RNA Conformational Modulators.
Pharmaceuticals (Basel). 2022 Jun 14;15(6):748. doi: 10.3390/ph15060748.
5
Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
Viruses. 2022 May 4;14(5):961. doi: 10.3390/v14050961.
6
Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells.
Nat Commun. 2022 Mar 2;13(1):1128. doi: 10.1038/s41467-022-28603-2.
7
Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion.
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9). doi: 10.1073/pnas.2117198119.
8
Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences.
Front Chem. 2021 Dec 23;9:802766. doi: 10.3389/fchem.2021.802766. eCollection 2021.
10
Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures.
Sci Adv. 2021 Nov 26;7(48):eabl6096. doi: 10.1126/sciadv.abl6096.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验